NHS inhibitors refer to compounds containing N-hydroxysuccinimide (NHS) esters, which are widely used in organic chemistry for conjugation reactions. NHS esters are highly reactive with primary amines, a functional group commonly found in biological molecules such as proteins and peptides. The inhibition process in NHS inhibitors involves blocking or modifying the function of active amines within a system, typically through covalent attachment of the NHS ester to the amine group. This chemical reaction forms a stable amide bond, which can prevent the amine from participating in other chemical reactions, effectively inhibiting its function. These inhibitors are particularly useful in studying biochemical processes where amine groups play a key role, as they allow researchers to specifically and irreversibly modify these groups under controlled conditions.
NHS esters, as part of NHS inhibitors, exhibit high selectivity toward amine groups under mild, aqueous conditions. This selectivity is due to the activated NHS ester group, which increases the electrophilicity of the carboxyl group to which it is attached, making it more reactive toward nucleophilic attack by amines. The reaction efficiency is typically enhanced in slightly alkaline environments, where the amine groups are more nucleophilic. NHS inhibitors are widely employed in bioconjugation strategies, such as labeling biomolecules or creating crosslinks between proteins and other biological targets. Their efficiency, specificity, and compatibility with aqueous solutions make them valuable tools in various chemical processes, including the study of macromolecular interactions, structural analysis, and the development of chemical probes for biochemical research.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Binds to actin monomers, preventing their polymerization, leading to a decrease in the filamentous actin (F-actin) that NHS relies on for cellular scaffolding and signaling. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Binds to the barbed ends of actin filaments, blocking polymerization and elongation, thereby disrupting the actin cytoskeleton that NHS regulates. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Stabilizes actin filaments and prevents their disassembly, altering the dynamics of the actin cytoskeleton and thus affecting NHS function which relies on actin remodeling. | ||||||
Swinholide A, Theonella swinhoei | 95927-67-6 | sc-205914 | 10 µg | $135.00 | ||
Severs actin filaments and prevents their reannealing, impacting the structural integrity of the actin network that NHS modulates. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibitor of ROCK kinase, which is involved in actin cytoskeleton organization. Consequently, this disrupts the cellular structures and processes that NHS is implicated in. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibits myosin light chain kinase (MLCK), leading to reduced phosphorylation of myosin light chains and affecting NHS's modulation of actin-based structures. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
Inhibits formin-mediated actin nucleation and elongation, interfering with F-actin formation that NHS is involved in organizing. | ||||||
Phalloidin | 17466-45-4 | sc-202763 | 1 mg | $234.00 | 33 | |
Binds tightly to F-actin, stabilizing it and preventing filament depolymerization, thus altering the actin structures that are essential for NHS function. | ||||||